Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Rais, M. Articles by Kahn, R. Search for Related Content PubMed Citation Articles by Rais, M. Articles by Kahn, R. Schizophrenia Spectrum Disorders Cannabis Other Neuroanatomy Related Article

Excessive Brain Volume Loss Over Time in Cannabis-Using First-Episode Schizophrenia Patients

OBJECTIVE: Cerebral gray matter volume reductions have been found to progress over time in schizophrenia, with larger decreases related to poorer outcome, which has also been associated with cannabis use in schizophrenia patients. Progressive gray matter changes in patients who use cannabis may be more extensive than in those who do not. METHOD: Patients with recent-onset schizophrenia (N=51) and matched healthy subjects (N=31) were included. For all subjects, magnetic resonance imaging scans were obtained at inclusion (T0) and at 5-year follow-up (T5). Nineteen patients used cannabis but no other illicit drugs; 32 patients did not use any drugs during the 5-year follow-up. At T5, clinical outcome was measured. Cumulative amount of antipsychotic medication during the interval was calculated. At T0 and T5, total brain, gray and white matter, and lateral and third ventricle volumes were measured. Univariate analysis of covariance and pairwise comparisons were performed. Result: Schizophrenia patients showed a larger gray matter volume decrease over time than healthy subjects. They also showed larger increases in lateral and third ventricle volumes than healthy subjects and patients who did not use cannabis during follow-up. This decrement was significantly more pronounced in the patients who continued to use cannabis. These differences could not be attributed to outcome or baseline characteristics. CONCLUSIONS: First-episode schizophrenia patients who use cannabis show a more pronounced brain volume reduction over a 5-year follow-up than patients with schizophrenia who do not use cannabis. These results may help explain some of the detrimental effects of cannabis use in schizophrenia.

Related Article:

In This Issue
Am J Psychiatry 2008 165: A50. [Full Text] [PDF]

This article has been cited by other articles:

				A. Gonzalez-Pinto, S. Alberich, S. Barbeito, M. Gutierrez, P. Vega, B. Ibanez, M. K. Haidar, E. Vieta, and C. Arango Cannabis and First-Episode Psychosis: Different Long-term Outcomes Depending on Continued or Discontinued Use Schizophr Bull, November 13, 2009; (2009) sbp126v1. [Abstract] [Full Text] [PDF]

				O. D. Howes and S. Kapur The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway Schizophr Bull, May 1, 2009; 35(3): 549 - 562. [Abstract] [Full Text] [PDF]

				P. Tanskanen, K. Ridler, G. K. Murray, M. Haapea, J. M. Veijola, E. Jaaskelainen, J. Miettunen, P. B. Jones, E. T. Bullmore, and M. K. Isohanni Morphometric Brain Abnormalities in Schizophrenia in a Population-Based Sample: Relationship to Duration of Illness Schizophr Bull, November 17, 2008; (2008) sbn141v1. [Abstract] [Full Text] [PDF]

				D. F. ZULLINO, L. WABER, and Y. KHAZAAL Cannabis and the Course of Schizophrenia Am J Psychiatry, October 1, 2008; 165(10): 1357 - 1358. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2008 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us